Regeneron Pharmaceuticals (REGN) Wins Pasatru Approval, Is The Upside Already Priced In?
Regeneron Pharmaceuticals (REGN) recently received FDA approval for Pasatru, a new rare disease therapy. Despite a significant 30.55% 90-day surge and a 42.21% 1-year total return, the stock, currently around $834.04, is considered about 10% overvalued based on analyst forecasts. However, Simply Wall St's discounted cash flow model suggests it is undervalued, implying a wide valuation gap.
Wealthfront Advisers LLC Invests $4.37 Million in Regeneron Pharmaceuticals, Inc. $REGN
Wealthfront Advisers LLC has acquired a new stake worth approximately $4.37 million in Regeneron Pharmaceuticals (NASDAQ:REGN). Other institutional investors like BlackRock Inc. and Norges Bank have also significantly increased their holdings in the biopharmaceutical company. Regeneron recently announced a quarterly dividend and received FDA approval for Pasatru, a treatment for a rare genetic disorder, though some analysts suggest the approval's impact may already be priced into the stock.
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For The First Adult FOP Treatment
Regeneron Pharmaceuticals (REGN) has received FDA approval for Pasatru (garetosmab-grts), marking the first treatment for adults with fibrodysplasia ossificans progressiva (FOP). This approval, based on Phase 3 trial results, expands Regeneron's portfolio into rare disease treatments and reinforces its strategy of developing precise, technology-driven therapies. While Pasatru's approval strengthens the company's pipeline and diversifies revenue streams beyond its core products, analysts note that the ultra-rare nature of FOP means the launch alone might not fully address concerns about the need for larger, more diversified revenue.
Ceredex Value Advisors LLC Acquires New Position in Regeneron Pharmaceuticals, Inc. $REGN
Ceredex Value Advisors LLC has acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the second quarter, purchasing 69,370 shares valued at approximately $43.255 million. This investment now represents 1.2% of Ceredex Value Advisors LLC's portfolio, making it their 14th largest holding. Other institutional investors have also recently adjusted their stakes in REGN, and the company has been in the news for FDA approval of a new drug, ongoing clinical trials, recent insider stock sales, and a declared quarterly dividend.
Telix advances radiopharmaceutical pipeline as H1 revenue reaches $477 million
Telix Pharmaceuticals reported significant progress in its radiopharmaceutical imaging and therapeutic pipeline during the first half of 2026, achieving a 22% year-on-year revenue increase to $477 million. The company invested $124 million in R&D, focusing on late-stage therapeutics and precision medicine, particularly advancing treatments for prostate, brain, and kidney cancers. Telix also expanded its manufacturing infrastructure and formed a strategic collaboration with Regeneron to develop next-generation radiopharmaceutical therapies.
Ultragenyx, after FDA speed bump, lands 1st gene therapy nod with green light in glycogen storage disease
Ultragenyx has received its first FDA gene therapy approval for Genglycos (pariglasgene brecaparvovec-opnr), an AAV gene therapy for glycogen storage disease type Ia (GSDIa). This approval comes just over a year after another of the company's gene therapy candidates faced a rejection due to manufacturing issues. Genglycos is designed to help patients with GSDIa reduce their reliance on cornstarch by restoring the deficient G6PC enzyme.
REGN Shareholder Alert: September 14, 2026 Lead Plaintiff Deadline in Regeneron Pharmaceuticals Securities Class Action - Contact SueWallSt
SueWallSt is alerting investors in Regeneron Pharmaceuticals (NASDAQ: REGN) about a securities class action lawsuit with a lead plaintiff deadline of September 14, 2026. The lawsuit alleges that the company made false and misleading statements between August 1, 2025, and May 15, 2026, leading to a significant stock drop after a protocol amendment for a Phase III study raised concerns about statistical significance. Investors who purchased shares during this period and suffered losses may be eligible to recover their investment.
Regeneron Secures FDA Approval for Rare Genetic Disorder Drug
Regeneron Pharmaceuticals, Inc. (REGN) has received FDA approval for Pasatru (garetosmab-grts) to treat fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder causing abnormal bone formation. This approval is based on strong results from the OPTIMA study, showing significant reduction in new lesions and flare-ups. The company is actively diversifying its portfolio beyond its lead drug Eylea and has other promising therapies in its pipeline, including a gene therapy for hearing loss and a C5-targeting RNAi therapy for myasthenia gravis.
Eupraxia Pharmaceuticals Market Sentiment
This article provides an overview of market sentiment for Eupraxia Pharmaceuticals (EPRX), including analyst consensus, short interest, options flow, and insider activity. It highlights that 6 analysts have a "Buy" consensus with an average price target of $16, indicating a significant upside. The article also lists recent analyst actions with their ratings and price target changes.
Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit
Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (REGN) following revelations about a failed Phase 3 clinical trial for a melanoma therapy, which caused an $11 billion market cap wipeout. The lawsuit alleges that Regeneron made false and misleading statements regarding the trial's statistical assumptions and the efficacy of its drug combination. Investors who purchased Regeneron common stock between August 1, 2025, and May 15, 2026, and suffered substantial losses, have until September 14, 2026, to apply to be lead plaintiff.
Regeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
Regeneron Pharmaceuticals (NASDAQ: REGN) has received FDA approval for Pasatru (garetosmab-grts), a new drug for adults with fibrodysplasia ossificans progressiva (FOP). This therapy aims to prevent the formation of new bone lesions and reduce flare-ups in this ultra-rare condition, which causes progressive bone growth in muscles and tendons. The approval was based on positive Phase 3 trial results showing significant reduction in new lesions and flare-ups.
REGENERNON PHARMACEUTICALS, INC. (REGN) SHAREHOLDER ALERT
Bernstein Liebhard LLP has issued a shareholder alert for Regeneron Pharmaceuticals, Inc. (REGN) investors, reminding them of an upcoming September 14, 2026 deadline for a securities fraud class action lawsuit. The lawsuit alleges that Regeneron made materially false and misleading statements between August 1, 2025, and May 15, 2026, leading to artificially inflated stock prices and investor losses. Investors who purchased shares during this period are encouraged to contact Bernstein Liebhard LLP to learn more about joining the class action.
Wave Life Sciences Inc (HAM:0VS) Stock Price, Trades & News
This article provides a detailed financial overview of Wave Life Sciences Inc (HAM:0VS), a clinical-stage biotechnology company. It covers stock price, key financial metrics like P/E, P/B, market cap, and enterprise value, alongside various performance ranks including financial strength, growth, momentum, and profitability. The report also lists upcoming stock events and addresses frequently asked questions about the company's stock and dividends.
E Fund Management Co. Ltd. Makes New $3.22 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
E Fund Management Co. Ltd. has made a new $3.22 million investment in Regeneron Pharmaceuticals, Inc., purchasing 5,158 shares. This comes as Regeneron reported strong quarterly earnings, surpassing analyst estimates, and received FDA approval for Pasatru, a treatment for a rare bone disorder. Despite a "Moderate Buy" consensus rating from analysts, the company faces ongoing securities litigation related to a failed melanoma trial.
DCF Advisers LLC Purchases New Holdings in Regeneron Pharmaceuticals, Inc. $REGN
DCF Advisers LLC has acquired a new stake of 9,250 shares in Regeneron Pharmaceuticals (NASDAQ:REGN), valued at approximately $5.77 million, making it their 14th largest holding. This comes as Regeneron reported strong quarterly earnings, beating estimates with $14.29 EPS and a 16.7% year-over-year revenue increase. The company also secured FDA approval for Pasatru, a treatment for a rare bone disorder, although it faces litigation concerning a failed melanoma trial.
REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses
Robbins LLP is reminding investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit alleges that Regeneron misled investors about its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, specifically regarding statistical assumptions and clinical differentiation. Investors who suffered losses between August 1, 2025, and May 15, 2026, are encouraged to contact Robbins LLP by September 14, 2026, to potentially serve as lead plaintiff.
REGN Stockholders Interested in Leading the Class Action Against Regeneron Pharmaceuticals, Inc. Should Contact Robbins LLP for Information About Recovering Their Losses
Robbins LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron misled investors about its Phase 3 Fianlimab-Libtayo clinical trial for advanced melanoma, failing to disclose flaws in statistical assumptions and a lack of clinical differentiation, which led to a significant stock price drop after the trial failed its primary endpoint. Investors who suffered losses during this period are encouraged to contact Robbins LLP by the September 14, 2026, deadline to seek appointment as lead plaintiff.
Telix Pharmaceuticals (ASX:TLX) Shares Rise Today as H1 Revenue Climbs 22% to US$477 Million
Telix Pharmaceuticals (ASX:TLX) saw its shares rise as it reported a 22% increase in H1 2026 revenue to US$477 million, with a gross margin of 55%. Adjusted EBITDA surged by 146% to US$52 million, and the company achieved a profit after tax of US$38 million, reversing a US$2 million loss from H1 2025. The Precision Medicine segment was a key driver of growth, and Telix anticipates FY26 revenue and other income to exceed US$1 billion.
Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress
Telix Pharmaceuticals (ASX: TLX) reported robust half-year results, with revenue up 22% to US$477 million and adjusted EBITDA surging 146% to US$52 million. The company made significant progress in pipeline development, strategic collaborations, and global manufacturing expansion. Telix reaffirmed its FY26 revenue guidance of over US$1 billion and expects continued clinical trial readouts and regulatory submissions.
Telix reports strong growth as late-stage cancer pipeline advances
Telix Pharmaceuticals reported a strong first half of 2026, with double-digit revenue growth and improved margins, driven by its Precision Medicine business and continued investment in its late-stage radiopharmaceutical pipeline. The company is on track to exceed US$1 billion in total revenue and other income for the full year, while also advancing therapeutic candidates in prostate cancer, kidney cancer, and glioblastoma. Telix is also pursuing several regulatory opportunities for its imaging portfolio and expanding its global manufacturing capabilities.
Ninth Circuit Revives Regeneron Kickback Whistleblower Lawsuit
A federal appeals court has partially revived a whistleblower lawsuit against Regeneron Pharmaceuticals Inc., alleging illegal kickbacks to physicians for prescribing its drugs. The Ninth Circuit Court of Appeals reversed a lower court's dismissal of the Anti-Kickback Statute claims under the False Claims Act, stating that while the existence of payments was public, the specific details of the alleged fraud were not. The lawsuit, brought by former Regeneron employees, claims the company systematically overpaid doctors, provided luxury travel, and paid for unheld educational events to induce prescriptions.
Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test
Regeneron's new drug, Pasatru, has received FDA approval for the treatment of FOP (fibrodysplasia ossificans progressiva). This approval is a significant test for Regeneron's strategy in the rare disease market. The article highlights the company's focus on this specific area of medicine.
Pasatru’s FDA Approval Puts Regeneron’s Rare-Disease Playbook To The Test
Regeneron's drug Pasatru has received FDA approval for the treatment of FOP. This approval is seen as a crucial test for Regeneron's strategy in the rare-disease market. The article suggests this event will highlight how Regeneron's approach to rare diseases fares following this significant regulatory milestone.
US FDA approves Regeneron's rare bone disorder drug
The U.S. FDA has approved Regeneron's experimental drug, garetosmab (branded as Pasatru), for the rare genetic disorder fibrodysplasia ossificans progressiva (FOP). The drug significantly reduced abnormal bone formation in soft tissues, with trials showing a 90-94% reduction in new bone abnormalities. This approval addresses a condition that affects approximately 1 in 2 million people worldwide, causing progressive loss of mobility due to soft tissues turning into bone.
Regeneron Pharmaceuticals Announces FDA Approval of Pasatru for Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals has received FDA approval for Pasatru™ (garetosmab-grts) to treat adults with fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder characterized by debilitating bone growth. The approval is based on Phase 3 OPTIMA trial results showing a 90-94% reduction in new heterotopic ossification lesions and a significant decrease in flare-ups. This intravenous treatment offers a new crucial therapy for the FOP community, with potential to greatly improve quality of life, despite some safety concerns and the small patient population.
Regeneron rare bone disorder therapy approved (REGN:NASDAQ)
The U.S. Food and Drug Administration (FDA) has approved Regeneron's drug, Pasatru, for treating fibrodysplasia ossificans progressiva (FOP), an ultra-rare bone growth disorder in adults. This approval follows the regulator's earlier decision to grant priority review for the company's Biologics License Application. This development marks a significant step for Regeneron in addressing unmet medical needs for patients with FOP.
REGN Investor Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron gave an overly positive view of its Phase III Fianlimab-Libtayo Study, minimizing risks associated with a protocol change and the trial's failure to meet its primary endpoint for progression-free survival. This led to a significant drop in REGN's stock price, causing losses for investors.
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and some of its officers. The lawsuit claims that Regeneron made false or misleading statements regarding its Phase III Fianlimab-Libtayo study, alleging fundamental flaws in its statistical assumptions and a lack of meaningful clinical differentiation from standard therapies. Investors who purchased Regeneron securities between August 1, 2025, and May 15, 2026, are encouraged to join the case, with a lead plaintiff deadline of September 14, 2026.
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo study, claiming the preliminary statistical assumptions were flawed and the study was unlikely to achieve statistical significance. Investors who suffered losses are encouraged to join the case by September 14, 2026.
Teva Rises 17% YTD: Should You Buy, Sell or Hold the Stock?
Teva Pharmaceutical Industries Limited (TEVA) has seen a 17.2% year-to-date increase in stock value due to strong operating performance, rising revenue expectations, and a successful "Pivot to Growth" strategy focusing on its branded portfolio and pipeline. The article examines Teva's strengths, such as its new innovative drugs Austedo, Ajovy, and Uzedy, and its expanding pipeline, alongside challenges like a heavy debt burden and competition in the generics market. Despite near-term profitability concerns related to an acquisition, the company's improving financial profile and long-term growth prospects make it a potential long-term hold, though short-term investors might consider exiting due to declining estimates.
Regeneron halts first-in-human REGN7041 trial after safety event
Regeneron has terminated its Phase I/II clinical trial for REGN7041, an anti-CD3 monoclonal antibody for non-infectious uveitis, after only one participant was enrolled due to a safety event. The company voluntarily ended the TITAN study following a risk-benefit reassessment, although the underlying cause of the event has not been identified. This early termination means the drug will not progress through its planned dose-escalation program, with no further development plans announced.
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD By Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) stock reached a new 52-week high of $821.41, reflecting a 42.43% return over the past year. The company's strong performance is attributed to advancements in its drug pipeline, strategic partnerships, and robust financial health, as highlighted by InvestingPro. Recent Q2 2026 results exceeded expectations, driven by strong sales of Dupixent, Eylea HD, and Libtayo, leading to increased price targets from analysts.
Regeneron Pharmaceuticals stock hits 52-week high at 821.41 USD
Regeneron Pharmaceuticals (NASDAQ: REGN) stock reached a new 52-week high of $821.41, reflecting a 42.43% total return over the past year. The company's strong performance is attributed to advancements in its drug pipeline, strategic partnerships, and robust Q2 2026 results which exceeded analyst expectations. Upward revisions in earnings forecasts and aggressive share buybacks further indicate positive investor sentiment and continued growth potential for the biotech giant.
Alvotech earnings on deck as FDA biosimilar decisions loom
Alvotech is set to report its second-quarter earnings, with investors keenly watching for signs of revenue growth and progress on critical FDA biosimilar approvals for Simponi and Eylea. Analysts anticipate a loss of 4 cents per share on revenue of $111.5 million. The company's ability to navigate regulatory hurdles, particularly after its manufacturing facility received a "Voluntary Action Indicated" classification, and its commercial strategy, especially concerning intellectual property, will be key to unlocking significant opportunities in the U.S. market.
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) on behalf of investors who purchased securities between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made misleading statements about the statistical assumptions and clinical differentiation of its Phase III Fianlimab-Libtayo study. Investors who suffered losses are encouraged to seek lead plaintiff status by September 14, 2026.
M. Kulyk & Associates LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
M. Kulyk & Associates LLC has made a new investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 12,878 shares valued at approximately $8.03 million in the second quarter. This investment makes Regeneron Pharmaceuticals the 29th largest holding for M. Kulyk & Associates LLC, accounting for 1.3% of their total holdings. Other hedge funds have also recently increased their positions in REGN, and the company reported strong Q2 earnings, exceeding analyst expectations for both EPS and revenue.
Pallas Capital Advisors LLC Takes $1.20 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
Pallas Capital Advisors LLC has acquired a new position of 1,920 shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), valued at approximately $1.20 million during the second quarter. Regeneron reported strong quarterly earnings, beating analyst estimates with an EPS of $14.29 and revenue of $4.29 billion, representing a 16.7% year-over-year increase. The company also declared a quarterly dividend of $0.94, and analysts maintain a "Moderate Buy" rating with an $801.70 target price, despite ongoing litigation risks.
Great Lakes Advisors LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN
Great Lakes Advisors LLC has made a new investment in Regeneron Pharmaceuticals, Inc. ($REGN), purchasing 16,928 shares worth approximately $10.6 million. This comes as Regeneron reported strong quarterly earnings, beating analyst estimates with an EPS of $14.29 and a 16.7% year-over-year revenue increase. However, the company faces ongoing litigation regarding alleged misleading disclosures related to a failed clinical trial, which has led to a class-action lawsuit.
Danske Bank A S Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN
Danske Bank A S has acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 104,676 shares valued at approximately $65.27 million. This investment makes Danske Bank A S the owner of 0.10% of Regeneron Pharmaceuticals. The article also highlights recent analyst ratings, financial performance, and insider trading activities for Regeneron.
Global Retirement Partners LLC Makes New $975,000 Investment in Regeneron Pharmaceuticals, Inc. $REGN
Global Retirement Partners LLC has made a new investment of $975,000 in Regeneron Pharmaceuticals, Inc. by purchasing 1,564 shares during the second quarter. Other institutional investors have also adjusted their holdings, with significant stakes held by various hedge funds and institutional investors. The article also details recent insider stock sales, analyst ratings, and the company's financial performance and dividend announcement.
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regeneron Pharmaceuticals, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit alleges that Regeneron made materially false or misleading statements regarding the preliminary statistical assumptions and prospects of its Phase III Fianlimab-Libtayo study. Shareholders who purchased Regeneron securities between August 1, 2025, and May 15, 2026, have until September 14, 2026, to request to be appointed as lead plaintiff.
REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) who suffered losses during the class period of August 1, 2025, to May 15, 2026. The lawsuit alleges that Regeneron made false and misleading statements regarding its Phase III Fianlimab-Libtayo Study, leading to a significant stock price decline after the study failed to meet its primary endpoint. Shareholders are encouraged to contact the firm to potentially be appointed as lead plaintiff before the September 14, 2026 deadline.
Regeneron ends eye disease study due to antibody’s safety profile
Regeneron has discontinued a Phase 1/2 study for REGN7041, an investigational anti-inflammatory antibody for non-infectious uveitis, due to an unfavorable benefit-risk assessment following an unspecified safety event. This setback adds to a series of recent clinical trial failures for Regeneron, increasing pressure from analysts for the company to pursue M&A opportunities despite its significant cash reserves. The company has clarified that it is open to external innovation and has recently entered into several partnerships.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
Bernstein Liebhard LLP has announced a securities class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) on behalf of investors who purchased shares between August 1, 2025, and May 15, 2026. The lawsuit alleges that Regeneron made materially false and misleading statements, leading to artificially inflated stock prices and significant losses for investors. Shareholders are encouraged to join the lawsuit by September 14, 2026.
Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile
Regeneron has terminated a Phase 1/2 study of its investigational anti-inflammatory antibody, REGN7041, for non-infectious uveitis due to an "unfavorable benefit-risk assessment." This marks another clinical setback for Regeneron, following failures of itepekimab for COPD and a melanoma combo. Despite these challenges, the company, while facing pressure for M&A, has been active in strategic partnerships to build its pipeline.
UNIVEST FINANCIAL Corp Takes $8.15 Million Position in Regeneron Pharmaceuticals, Inc. $REGN
UNIVEST FINANCIAL Corp has acquired a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 13,072 shares valued at approximately $8.15 million during the second quarter. This move is part of broader institutional interest, with several other hedge funds and institutional investors also increasing their stakes in the biopharmaceutical company. Insider activity at Regeneron includes recent sales by Director Huda Y. Zoghbi and Director Arthur F. Ryan.
Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP
Hagens Berman Sobol Shapiro LLP has filed a securities class action lawsuit against Regeneron Pharmaceuticals (NASDAQ: REGN) on behalf of investors who incurred substantial losses. The lawsuit alleges that Regeneron made false and misleading statements regarding a Phase 3 clinical trial for a melanoma therapy, which ultimately failed to meet its primary endpoint. Investors who purchased Regeneron stock between August 1, 2025, and May 15, 2026, are encouraged to come forward to lead the class action.
Perigon Wealth Management LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN
Perigon Wealth Management LLC has acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), purchasing 7,164 shares valued at approximately $4.467 million during the second quarter. This move comes as several other institutional investors have also adjusted their holdings in the biopharmaceutical company. Meanwhile, company insiders have recently sold shares, and analysts have issued various ratings and price targets for REGN.
4,376 Shares in Regeneron Pharmaceuticals, Inc. $REGN Purchased by Citizens Financial Group Inc. RI
Citizens Financial Group Inc. RI recently acquired 4,376 shares of Regeneron Pharmaceuticals (NASDAQ:REGN) valued at approximately $2.73 million. Regeneron reported strong quarterly earnings, exceeding consensus estimates with EPS of $14.29 and revenue of $4.29 billion, a 16.7% increase year-over-year. Analysts maintain a "Moderate Buy" rating for REGN, with an average price target of $801.70.
Deutsche Bank AG Makes New $323.25 Million Investment in Regeneron Pharmaceuticals, Inc. $REGN
Deutsche Bank AG has made a significant new investment of $323.25 million in Regeneron Pharmaceuticals, acquiring over half a million shares, which represents about 0.49% of the company. This comes as Regeneron reported strong quarterly earnings, beating analyst estimates, and maintains a "Moderate Buy" consensus rating with an average price target of $801.70. Institutional investors now collectively own 83.31% of REGN, while some insiders have recently sold shares.
